|
|
Blood, 1 October 2005, Vol. 106, No. 7, pp. 2527-2529.
Prepublished online as a Blood First Edition Paper on May 31, 2005; DOI 10.1182/blood-2005-02-0540.
Previous Article | Next Article 
Submitted February 9, 2005
Accepted May 16, 2005
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression
Ugo Testa*, Roberta Riccioni, Mauro Biffoni, Daniela Diverio, Francesco Lo-Coco, Robin Foa, Cesare Peschle, and Arthur E Frankel
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
Hematology, Department of Cellular Biotechnologies and Hematology, University "La Sapienza", Rome, Italy
Department of Biopathology, University of Tor Vergata, Rome, Italy
Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
* Corresponding author; email: u.testa{at}iss.it.
Leukemic blasts from patients with acute myeloid leukemia (AML) frequently express high levels of the interleukin-3 receptor chain (IL-3R ). In the present study, we have explored the sensitivity of primary leukemic blasts obtained from 34 AML patients to a diphtheria toxin (DT) composed of the catalytic and translocation domains of DT (DT388) fused to IL-3 (DT388IL-3) and to DT388 fused to a variant IL-3 with increased binding affinity (DT388IL-3[K116W]). On a molar basis, DT388IL-3[K116W] was significantly more active than DT388IL-3 in mediating leukemic cell killing. The rate of cell killing induced by the two DT/IL-3 fusion proteins was significantly correlated with the level of IL-3R /IL-3R expressed on leukemic blasts. These observations support a potential use of DT388IL-3[K116W] in the treatment of refractory AMLs and provide a simple biochemical parameter for the selection of eligible patients.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Djokic, E. Bjorklund, E. Blennow, J. Mazur, S. Soderhall, and A. Porwit
Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
Haematologica,
July 1, 2009;
94(7):
1016 - 1019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen, J. Olsen, S. Ford, S. Mirza, A. Walker, J. M. Murphy, and I. G. Young
A New Isoform of Interleukin-3 Receptor {alpha} with Novel Differentiation Activity and High Affinity Binding Mode
J. Biol. Chem.,
February 27, 2009;
284(9):
5763 - 5773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Singh, U. Samant, S. Hyland, P. R. Chaudhari, W. S. Wels, and D. Bandyopadhyay
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors
Mol. Cancer Ther.,
February 1, 2007;
6(2):
562 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yalcintepe, A. E. Frankel, and D. E. Hogge
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice
Blood,
November 15, 2006;
108(10):
3530 - 3537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Hogge, L. Yalcintepe, S.-H. Wong, B. Gerhard, and A. E. Frankel
Variant Diphtheria Toxin-Interleukin-3 Fusion Proteins with Increased Receptor Affinity Have Enhanced Cytotoxicity against Acute Myeloid Leukemia Progenitors
Clin. Cancer Res.,
February 15, 2006;
12(4):
1284 - 1291.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|